Literature DB >> 24746253

Matrix metalloproteinase levels in chronic thoracic aortic dissection.

Xiaoming Zhang1, Darrell Wu2, Justin C Choi3, Charles G Minard4, Xinguo Hou3, Joseph S Coselli3, Ying H Shen3, Scott A LeMaire5.   

Abstract

BACKGROUND: Imbalance between matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) can lead to aortic wall failure. We hypothesized that patients with aneurysms resulting from chronic descending thoracic aortic dissection have elevated tissue and plasma levels of specific MMPs and decreased tissue levels of TIMPs.
MATERIALS AND METHODS: Aortic tissue was obtained from 25 patients who required surgical repair of descending thoracic aortic aneurysm due to chronic aortic dissection and from 17 organ-donor controls without aortic disease. Tissue levels of MMP-1, -2, -3, -9, -12, and -13 and TIMP-1 and -2 were measured by colorimetric activity assay or enzyme-linked immunosorbent assay and confirmed by Western blot and immunohistochemistry. Blood obtained from the 25 patients and 15 controls without aortic diseases was used to compare plasma levels of MMP-3, -9, and -12.
RESULTS: Total MMP-1, total MMP-9, and active MMP-9 levels were higher and total MMP-2 levels were lower in dissection tissue than in control tissue. Additionally, the MMP-9 to TIMP-1 and active to total MMP-2 ratios were higher and the MMP-2 to TIMP-2 ratio was lower in dissection tissue. Furthermore, patients had higher plasma active to total MMP-9 ratios than the controls. Age and hypertension were associated with increased MMP levels.
CONCLUSIONS: Increased levels of several MMPs and increased MMP to TIMP ratios in aortic tissue from patients suggest an environment that favors proteolysis, which may promote progressive extracellular matrix destruction and medial degeneration after aortic dissection. An elevated active to total MMP-9 ratio in plasma may be a biomarker for end-stage aneurysm development in patients with chronic thoracic aortic disease.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aortic dissection; Matrix metalloproteinase; Tissue inhibitor of metalloproteinases

Mesh:

Substances:

Year:  2014        PMID: 24746253      PMCID: PMC4065027          DOI: 10.1016/j.jss.2014.03.027

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  26 in total

1.  Proteolysis of the abdominal aortic aneurysm wall and the association with rupture.

Authors:  E Petersen; F Wågberg; K A Angquist
Journal:  Eur J Vasc Endovasc Surg       Date:  2002-02       Impact factor: 7.069

Review 2.  An overview of matrix metalloproteinases in the pathogenesis and treatment of abdominal aortic aneurysms.

Authors:  W Brent Keeling; Paul A Armstrong; Patrick A Stone; Dennis F Bandyk; Murray L Shames
Journal:  Vasc Endovascular Surg       Date:  2005 Nov-Dec       Impact factor: 1.089

3.  Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome.

Authors:  A M Segura; R E Luna; K Horiba; W G Stetler-Stevenson; H A McAllister; J T Willerson; V J Ferrans
Journal:  Circulation       Date:  1998-11-10       Impact factor: 29.690

4.  Collagen and elastin degradation by matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase in aortic dissection.

Authors:  T Ishii; N Asuwa
Journal:  Hum Pathol       Date:  2000-06       Impact factor: 3.466

5.  Matrix metalloproteinases in ascending aortic aneurysms: bicuspid versus trileaflet aortic valves.

Authors:  Scott A LeMaire; Xinwen Wang; Jonathan A Wilks; Stacey A Carter; Shixiang Wen; Taehee Won; Dominic Leonardelli; Gobind Anand; Lori D Conklin; Xing Li Wang; Robert W Thompson; Joseph S Coselli
Journal:  J Surg Res       Date:  2005-01       Impact factor: 2.192

Review 6.  Matrix metalloproteinases in vascular physiology and disease.

Authors:  Suzanne A Siefert; Rajabrata Sarkar
Journal:  Vascular       Date:  2012-08-15       Impact factor: 1.285

7.  Increased tissue microarray matrix metalloproteinase expression favors proteolysis in thoracic aortic aneurysms and dissections.

Authors:  George J Koullias; Pars Ravichandran; Dimitris P Korkolis; David L Rimm; John A Elefteriades
Journal:  Ann Thorac Surg       Date:  2004-12       Impact factor: 4.330

8.  Altered patterns of gene expression specific to thoracic aortic aneurysms: microarray analysis of surgically resected specimens.

Authors:  Tsuyoshi Taketani; Yasushi Imai; Tetsuro Morota; Koji Maemura; Hiroyuki Morita; Dobun Hayashi; Tsutomu Yamazaki; Ryozo Nagai; Shinichi Takamoto
Journal:  Int Heart J       Date:  2005-03       Impact factor: 1.862

9.  Decreased tissue inhibitor of metalloproteinase-2/matrix metalloproteinase ratio in the acute phase of aortic dissection.

Authors:  Takahiro Manabe; Kiyotaka Imoto; Keiji Uchida; Chiharu Doi; Yoshinori Takanashi
Journal:  Surg Today       Date:  2004       Impact factor: 2.549

10.  Immunohistochemical expression of metalloproteinases MMP-2 and MMP-9 in abdominal aortic aneurysms: correlation with symptoms and aortic diameter.

Authors:  Efstathios Papalambros; Fragiska Sigala; Sotiris Georgopoulos; Charalambos Menekakos; Alexandra Giatromanolaki; Elias Bastounis; Efthymios Sivridis
Journal:  Int J Mol Med       Date:  2003-12       Impact factor: 4.101

View more
  22 in total

Review 1.  Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis.

Authors:  Mingyi Wang; Soo Hyuk Kim; Robert E Monticone; Edward G Lakatta
Journal:  Hypertension       Date:  2015-02-09       Impact factor: 10.190

Review 2.  Clinical-pathological correlations of BAV and the attendant thoracic aortopathies. Part 2: Pluridisciplinary perspective on their genetic and molecular origins.

Authors:  Ares Pasipoularides
Journal:  J Mol Cell Cardiol       Date:  2019-06-06       Impact factor: 5.000

Review 3.  Molecular pathogenesis of genetic and sporadic aortic aneurysms and dissections.

Authors:  Ying H Shen; Scott A LeMaire
Journal:  Curr Probl Surg       Date:  2017-02-03       Impact factor: 1.909

4.  Left ventricular hypertrophy is a possible biomarker for early mortality after type B aortic dissection.

Authors:  Alexander P Taylor; Rosario V Freeman; Matthew A Bartek; Sherene Shalhub
Journal:  J Vasc Surg       Date:  2018-12-11       Impact factor: 4.268

5.  The genetic basis of Turner syndrome aortopathy.

Authors:  Holly Corbitt; Jacob Gutierrez; Michael Silberbach; Cheryl L Maslen
Journal:  Am J Med Genet C Semin Med Genet       Date:  2019-02-16       Impact factor: 3.908

6.  Differential regulation of matrix metalloproteinases in varicella zoster virus-infected human brain vascular adventitial fibroblasts.

Authors:  Maria A Nagel; Alexander Choe; April Rempel; Ann Wyborny; Kurt Stenmark; Don Gilden
Journal:  J Neurol Sci       Date:  2015-09-16       Impact factor: 3.181

7.  GDF11 prevents the formation of thoracic aortic dissection in mice: Promotion of contractile transition of aortic SMCs.

Authors:  Kai Ren; Buying Li; Zhenhua Liu; Lin Xia; Mengen Zhai; Xufeng Wei; Weixun Duan; Shiqiang Yu
Journal:  J Cell Mol Med       Date:  2021-03-25       Impact factor: 5.310

8.  β-Aminopropionitrile monofumarate induces thoracic aortic dissection in C57BL/6 mice.

Authors:  Weihong Ren; Yan Liu; Xuerui Wang; Lixin Jia; Chunmei Piao; Feng Lan; Jie Du
Journal:  Sci Rep       Date:  2016-06-22       Impact factor: 4.379

9.  Mechanical Strain Induced Expression of Matrix Metalloproteinase-9 via Stretch-Activated Channels in Rat Abdominal Aortic Dissection.

Authors:  ZhiHuang Qiu; LiangWan Chen; Hua Cao; Qiang Chen; Hua Peng
Journal:  Med Sci Monit       Date:  2017-03-13

10.  TIMP3 and TIMP1 are risk genes for bicuspid aortic valve and aortopathy in Turner syndrome.

Authors:  Holly Corbitt; Shaine A Morris; Claus H Gravholt; Kristian H Mortensen; Rebecca Tippner-Hedges; Michael Silberbach; Cheryl L Maslen
Journal:  PLoS Genet       Date:  2018-10-03       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.